CRISPR-Cas9 genome editing has recently been used in tumor organoids to introduce mutations into genes commonly found mutated such as Trp53, Brca1, Nf1, and Pten in high-grade serous ovarian cancer (Lõhmussaar et al., 2020). This evidence concerns the gene TP53 and ovarian serous adenocarcinoma.